Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

February 19, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine to Present at SVB Leerink 10th Annual Global Healthcare Conference

SAN DIEGO, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
February 16, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine Announces Publication of MET409 NASH Proof-of-Concept Study Results in the Journal of Hepatology

SAN DIEGO, Feb. 16, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
January 19, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine Announces FDA Fast Track Designation for MET642 as a Treatment of NASH

SAN DIEGO, Jan. 19, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
January 05, 2021 06:30 ET | Source: Metacrine, Inc.

Metacrine Initiates Phase 2a Combination Trial of MET409 with Empagliflozin in Patients with Type 2 Diabetes and NASH

SAN DIEGO, Jan. 05, 2021 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
December 17, 2020 06:30 ET | Source: Metacrine, Inc.

Metacrine Reports Positive Results from Phase 1 Trial of MET642

MET642 Demonstrated Sustained Pharmacokinetic Profile and Robust FXR Target Engagement with Once-Daily Oral Dosing, without Pruritis or LDL-Cholesterol Increase Doses Selected for Phase 2a Trial in...
November 23, 2020 06:30 ET | Source: Metacrine, Inc.

Metacrine to Participate in Upcoming Investor Conferences

SAN DIEGO, Nov. 23, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
November 12, 2020 06:30 ET | Source: Metacrine, Inc.

Metacrine Reports Business Updates and Third Quarter 2020 Financial Results

Upcoming Data at AASLD Support Robust, Sustained FXR Activation by MET409 in Patients with NASH $85 Million Initial Public Offering Completed SAN DIEGO, Nov. 12, 2020 (GLOBE...
October 01, 2020 16:01 ET | Source: Metacrine, Inc.

Metacrine to Present New Data from MET409 Program in NASH at AASLD’s The Liver Meeting Digital Experience™

SAN DIEGO, Oct. 01, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
September 15, 2020 21:52 ET | Source: Metacrine, Inc.

Metacrine Announces Pricing of Initial Public Offering

SAN DIEGO, Sept. 15, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc. (Nasdaq: MTCR), a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies for patients...
September 02, 2020 07:30 ET | Source: Metacrine, Inc.

Metacrine Strengthens Leadership Team with Key Appointments

SAN DIEGO, Sept. 02, 2020 (GLOBE NEWSWIRE) -- Metacrine, Inc., a clinical-stage biopharmaceutical company focused on discovering and developing differentiated therapies to treat patients with liver...

keyboard_arrow_left Previous Page

Next Page keyboard_arrow_right